Victoria Saferding

Victoria Saferding

Auto-generated profile, based on publicly available information

Victoria Saferding

Department of Rheumatology, Medical University Vienna, Austria

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 August 2014 in The Journal of Immunology
Verified
Journal Article
Closed access
ESEmine Sahin
Emine Sahin
SHStefan Haubenwallner
Stefan Haubenwallner
MKMario Kuttke
Mario Kuttke
IKIsabella Kollmann
Isabella Kollmann
AHAngela Halfmann
Angela Halfmann
GSGernot Schabbauer
Gernot Schabbauer
The activation of innate immune cells triggers numerous intracellular signaling pathways, which require tight control to mount an adequate immune response. The PI3K signaling pathway is intricately involved in innate immunity, and its activation dampens the expression and release of proinflammatory cytokines in myeloid cells. These signaling processes are strictly regulated by the PI3K antagonist, the lipid phosphatase, PTEN, a known tumor suppressor. Importantly, PTEN is responsible for the elevated production of cytokines such as IL-6 in response to TLR agonists, and deletion of PTEN results in diminished inflammatory responses. However, the mechanisms by which PI3K negatively regulates TLR signaling are only partially resolved. We observed that Arginase I expression and secretion were markedly induced by PTEN deletion, suggesting PTEN−/− macrophages were alternatively activated. This was mediated by increased expression and activation of the transcription factors C/EBPβ and STAT3. Genetic and pharmacologic experimental approaches in vitro, as well as in vivo autoimmunity models, provide convincing evidence that PI3K/PTEN-regulated extracellular Arginase I acts as a paracrine regulator of inflammation and immunity.

1 June 2020 in Journal of Autoimmunity
Verified
Journal Article
Closed access
VSVictoria Saferding
Victoria Saferding
SBStephan Blüml
Stephan Blüml

1 October 2018 in Annals of the Rheumatic Diseases
Verified
Journal Article
Open access
PDF file
APAntonia Puchner
Antonia Puchner
VSVictoria Saferding
Victoria Saferding
MBMichael Bonelli
Michael Bonelli
YMYohei Mikami
Yohei Mikami
MHMelanie Hofmann
Melanie Hofmann
SBStephan Blüml
Stephan Blüml
Objectives Bone destruction in rheumatoid arthritis is mediated by osteoclasts (OC), which are derived from precursor cells of the myeloid lineage. The role of the two monocyte subsets, classical monocytes (expressing CD115, Ly6C and CCR2) and non-classical monocytes (which are CD115 positive, but low in Ly6C and CCR2), in serving as precursors for OC in arthritis is still elusive. Methods We investigated CCR2−/− mice, which lack circulating classical monocytes, crossed into hTNFtg mice for the extent of joint damage. We analysed monocyte subsets in hTNFtg and K/BxN serum transfer arthritis by flow cytometry. We sorted monocyte subsets and analysed their potential to differentiate into OC and their transcriptional response in response to RANKL by RNA sequencing. With these data, we performed a gene ontology enrichment analysis and gene set enrichment analysis. Results We show that in hTNFtg arthritis local bone erosion and OC generation are even enhanced in the absence of CCR2. We further show the numbers of non-classical monocytes in blood are elevated and are significantly correlated with histological signs of joint destruction. Sorted non-classical monocytes display an increased capacity to differentiate into OCs. This is associated with an increased expression of signal transduction components of RANK, most importantly TRAF6, leading to an increased responsiveness to RANKL. Conclusion Therefore, non-classical monocytes are pivotal cells in arthritis tissue damage and a possible target for therapeutically intervention for the prevention of inflammatory joint damage.

22 January 2020 in Nature Communications
Verified
Journal Article
Open access
PDF file
JBJulia S. Brunner
Julia S. Brunner
LVLoan Vulliard
Loan Vulliard
MHMelanie Hofmann
Melanie Hofmann
MKMarkus Kieler
Markus Kieler
ALAlexander Lercher
Alexander Lercher
GSGernot Schabbauer
Gernot Schabbauer
Multinucleated giant cells (MGCs) are implicated in many diseases including schistosomiasis, sarcoidosis and arthritis. MGC generation is energy intensive to enforce membrane fusion and cytoplasmic expansion. Using receptor activator of nuclear factor kappa-Β ligand (RANKL) induced osteoclastogenesis to model MGC formation, here we report RANKL cellular programming requires extracellular arginine. Systemic arginine restriction improves outcome in multiple murine arthritis models and its removal induces preosteoclast metabolic quiescence, associated with impaired tricarboxylic acid (TCA) cycle function and metabolite induction. Effects of arginine deprivation on osteoclastogenesis are independent of mTORC1 activity or global transcriptional and translational inhibition. Arginine scarcity also dampens generation of IL-4 induced MGCs. Strikingly, in extracellular arginine absence, both cell types display flexibility as their formation can be restored with select arginine precursors. These data establish how environmental amino acids control the metabolic fate of polykaryons and suggest metabolic ways to manipulate MGC-associated pathologies and bone remodelling.

1 March 2020 in Journal of Autoimmunity
Verified
Journal Article
Closed access
LGLisa Göschl
Lisa Göschl
TPTeresa Preglej
Teresa Preglej
NBNicole Boucheron
Nicole Boucheron
VSVictoria Saferding
Victoria Saferding
LMLena Müller
Lena Müller
MBMichael Bonelli
Michael Bonelli

3 November 2010 in Breast Cancer Research and Treatment
Verified
Journal Article
Closed access
PDF file
CBCaroline Brünner-Kubath
Caroline Brünner-Kubath
WSWaheed Shabbir
Waheed Shabbir
VSVictoria Saferding
Victoria Saferding
RWRenate Wagner
Renate Wagner
CSChristian F. Singer
Christian F. Singer
TGThomas W. Grunt
Thomas W. Grunt